Skip to main content
. 2013 Feb;2(1):40–49. doi: 10.3978/j.issn.2218-6751.2012.12.05

Table 3. Comparison of best reported phase II results for EGFR TKIs in patients with EGFR-Mutant lung cancers (Exon 19 and Exon 21).

Pts Enrolled, N RR, % mPFS, mos mOS, mos
Dacomitinib (57) 46             74             17 NR
Afatinib (53) 129*             66             15 32-39
Erlotinib (61) 33             70             14 31
Gefitinib (62) 27             59   9.2     17.5

*51 treated first-line